IP Library Granted Patent US 10,364,284
Granted Patent B2
US 10,364,284 · App. 15/839,403 · Granted Jul 30, 2019

High affinity antibodies that neutralize

Inventors: Philip M. Sass (Audubon, PA); Nicholas C. Nicolaides (Garnet Valley, PA); Luigi Grasso (Bala Cynwyd, PA); Marc Berger (Yardley, PA); Tao Sai (Foster City, CA)
Assignee: Eisai, Inc.
C07K16/1271C07K16/12A61K2039/505C07K2317/21C07K2317/565C07K2317/567C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,364,284
App. No.
15/839,403
Granted
Jul 30, 2019
Kind
B2
Abstract

Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.

Claims (4)

1. A recombinant antibody, said antibody comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 68, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 69, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 70, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 56, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 57, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 58, or an antigen-binding fragment thereof, that binds to Staphylococcus enterotoxin B with a dissociation constant (K D ) of less than 3×10 −8 M.

2. The antibody of claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 176 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 174, or an antigen-binding fragment thereof.

3. The antibody of claim 1 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 30 and the light chain comprises the amino acid sequence of SEQ ID NO: 28, or an antigen-binding fragment thereof.

4. A composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2018
From: MORPHOTEK, INC.
To: EISAI, INC.
Reel/Frame 046497/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2018
From: SASS, PHILIP M.; NICOLAIDES, NICHOLAS C.; GRASSO, LUIGI; BERGER, MARC; SAI, TAO
To: MORPHOTEK, INC.
Reel/Frame 046165/0539 →
Continuity (8)
Division 15144334 · May 2, 2016
Division 14515146 · Oct 15, 2014
Division 13943060 · Jul 16, 2013
Continuation 13540330 · Jul 2, 2012
Division 11969097 · Jan 3, 2008
Provisional Application 60883271 · Jan 3, 2007
Provisional Application 60888405 · Feb 6, 2007
Related Publication 20180094048A1 · Apr 5, 2018